US Patent 7241796 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease

Patent 7241796 was granted and assigned to Vertex Pharmaceuticals on July, 2007 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Vertex Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

7241796

Date of Patent

July 10, 2007

Patent Application Number

10280940

Date Filed

October 24, 2002

Patent Primary Examiner

‌

Cecilia J. Tsang

Patent abstract

The present invention relates to peptidomimetic compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3–NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7241796 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API